Compare Quest Diagnostics Inc (DGX) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Enovix Corporation — how do they compare? Quest Diagnostics Inc trades at $204.59 (market cap $22.80B), while Enovix Corporation trades at $5.13 (market cap $1.10B). The key difference: Quest Diagnostics Inc is far larger — about 20.7× Enovix Corporation's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| DGX | ENVX | |
|---|---|---|
Market Cap | $22.80B | $1.10B |
Sector | Health | Technology |
52-Week High | $216.02 | $15.93 |
52-Week Low | $166.42 | $4.84 |
Enterprise Value | $28.82B | $1.12B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ENVX trades at $4.95, down 4.81% with bearish technical signals despite recent earnings beats. The company shows negative profitability with -499.64% net margin and -$156.74M net loss for 2025, though revenue grew to $31.82M. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in battery technology commercialization.
While analyst consensus remains bullish with a $12.75 price target, significant execution risks persist given negative cash flows and high valuation multiples. The stock presents high-risk speculation on Enovix's ability to scale production and achieve profitability in the competitive battery technology market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
